ZyVersa Therapeutics (ZVSA) News Today → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free ZVSA Stock Alerts $5.34 -0.26 (-4.64%) (As of 03:04 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWhat's Going On With ZyVersa Stock?msn.com - April 29 at 1:03 PMmarketbeat.com - April 29 at 10:02 AMZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Diseasefinance.yahoo.com - April 29 at 8:02 AMZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Diseaseglobenewswire.com - April 29 at 7:57 AMmarketbeat.com - April 26 at 6:04 AMZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetesglobenewswire.com - April 4 at 7:57 AMZyVersa Therapeutics Stock (NASDAQ:ZVSA), Quotes and News Summarybenzinga.com - April 3 at 1:34 AMBuy Rating Affirmed: ZyVersa Therapeutics’ Promising Pipeline and Strategic Advancementsmarkets.businessinsider.com - March 27 at 10:09 AMZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 25 at 8:17 AMZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Diseaseglobenewswire.com - March 18 at 7:57 AMZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024finance.yahoo.com - March 14 at 9:55 AMZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024globenewswire.com - March 14 at 7:57 AMAnalysts Are Bullish on Top Healthcare Stocks: ACELYRIN, INC. (SLRN), ZyVersa Therapeutics (ZVSA)markets.businessinsider.com - March 13 at 2:03 PMBuy Rating Affirmed for ZyVersa Therapeutics Amid Promising Inflammatory and Metabolic Syndrome Treatmentsmarkets.businessinsider.com - February 29 at 3:08 PMZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesityglobenewswire.com - February 29 at 7:57 AMZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complicationsfinance.yahoo.com - February 28 at 9:09 AMZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complicationsglobenewswire.com - February 28 at 7:57 AMWhat In The World Is Going On With ZyVersa Therapeutics (ZVSA) Stock?msn.com - February 26 at 12:38 PMmarketbeat.com - February 26 at 9:46 AMmarketbeat.com - February 26 at 9:42 AMmarketbeat.com - February 26 at 9:38 AMWhy Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?investorplace.com - February 26 at 7:55 AMZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Optionfinance.yahoo.com - February 22 at 9:42 AMZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Optionglobenewswire.com - February 22 at 7:47 AMZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseasesfinance.yahoo.com - February 14 at 9:32 AMZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseasesglobenewswire.com - February 14 at 7:53 AMZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestonesfinance.yahoo.com - February 7 at 4:14 PMZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetesfinance.yahoo.com - January 31 at 9:42 AMZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Diseasefinance.yahoo.com - January 24 at 9:36 AMWhy Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?msn.com - January 17 at 12:56 PMZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasisfinance.yahoo.com - January 17 at 7:55 AMZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Accessfinance.yahoo.com - January 10 at 10:34 AMZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Marketsfinance.yahoo.com - January 4 at 9:28 AMZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024finance.yahoo.com - January 3 at 9:13 AMThis Biotech Is Targeting Indications Worth $70 Billionbenzinga.com - December 22 at 5:20 PMZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”finance.yahoo.com - December 18 at 9:36 AMBuy Rating Affirmed for ZyVersa Therapeutics Amid Promising Clinical Trials and Solid Financial Positionmarkets.businessinsider.com - December 16 at 10:04 AMZyVersa Therapeutics (ZVSA) Price Target Increased by 860.00% to 24.48msn.com - December 16 at 10:04 AMZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200finance.yahoo.com - December 14 at 9:33 AMZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200finance.yahoo.com - December 14 at 9:33 AMZyVersa Therapeutics, Inc. (ZVSA)uk.finance.yahoo.com - December 8 at 11:37 AMZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetesfinance.yahoo.com - December 7 at 3:33 PMmarketbeat.com - December 7 at 11:36 AMZyVersa Therapeutics Shares Slide Premarket After Offeringmarketwatch.com - December 7 at 10:24 AMWhy Is Cerevel Therapeutics (CERE) Stock Up 12% Today?markets.businessinsider.com - December 7 at 10:24 AMWhy ZyVersa Therapeutics Shares Are Down 40%benzinga.com - December 7 at 10:24 AMWhy Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today?msn.com - December 7 at 10:24 AMmarketbeat.com - December 7 at 10:13 AMZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offeringfinance.yahoo.com - December 6 at 10:34 PMZyVersa Jumps 32% After AIM2 And NLRP3 Inflammasomes Promote Atherosclerosis In Diabetesmarkets.businessinsider.com - December 6 at 12:33 PM Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address 1970’s computer coder Issues Shocking AI Warning (Ad)Louis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans. Click here to watch his new video ASAP ZVSA Media Mentions By Week ZVSA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVSA News Sentiment▼0.000.36▲Average Medical News Sentiment ZVSA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVSA Articles This Week▼02▲ZVSA Articles Average Week Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNGX News GTBP News EVOK News SEEL News THAR News LGVN News GNPX News ENSC News DRUG News ARTL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVSA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge AlertsThings Are Not Normal in America – Here’s What to DoStansberry Research1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
